文献速递关节外科

全髋关节置换术后抗凝模式变化:美国利伐沙班与华法林的深静脉血栓、肺栓塞及并发症频率

Changing Patterns of Anticoagulation After Total Hip Arthroplasty in the United States: Frequency of Deep Vein Thrombosis, Pulmonary Embolism, and Complications With Rivaroxaban and Warfarin.
PubMed 文献 · J Arthroplasty · 2019-03-31

该回顾性数据库分析利用2010至2015年Truven Health MarketScan理赔数据,评估择期全髋关节置换术后抗凝趋势及利伐沙班与华法林的有效性和安全性。华法林使用随时间下降而利伐沙班自2011至2015年增加;华法林使用者发生深静脉血栓和肺栓塞的比值比显著更高,两组出血率无显著差异,但华法林组假体周围关节感染比值比更高。

要点

  • 择期全髋关节置换术后华法林使用逐年减少,利伐沙班使用自2011至2015年增加。
  • 华法林组深静脉血栓和肺栓塞的比值比显著高于利伐沙班组。
  • 两组出血率无显著差异,但华法林组假体周围关节感染比值比更高。

核心结论

  • 在4年期间择期全髋关节置换术后利伐沙班预防性抗凝增加而华法林使用减少。
  • 华法林使用者较利伐沙班使用者更可能发生深静脉血栓和肺栓塞,且出血风险相似。

研究设计与样本

  • 回顾性数据库分析,使用Truven Health MarketScan数据库(2010-2015)的医疗理赔数据。
  • 纳入接受择期全髋关节置换术的患者,随访术后抗凝药使用情况。
  • 采用逻辑回归模型比较华法林与利伐沙班使用者术后90天内深静脉血栓、肺栓塞及不良事件的差异。
  • 使用逆概率治疗加权校正选择偏倚。

主要发现

  • 商业保险患者中华法林使用者12876例、利伐沙班使用者10892例;Medicare补充保险患者中华法林使用者7416例、利伐沙班使用者4739例。
  • 华法林使用在两个保险队列中随时间下降,而利伐沙班使用自2011至2015年增加。
  • 华法林使用者发生深静脉血栓的比值比显著更高(商业保险:比值比2.63,95%置信区间1.97-3.50;Medicare补充保险:比值比1.78,95%置信区间1.38-2.29)。
  • 华法林使用者发生肺栓塞的比值比显著更高(商业保险:比值比2.60,95%置信区间2.04-3.31;Medicare补充保险:比值比2.09,95%置信区间1.66-2.65)。
  • 两种药物出血率无显著差异,但华法林使用者假体周围关节感染比值比更高(商业保险:比值比1.57,95%置信区间1.16-2.13;Medicare补充保险:比值比1.79,95%置信区间1.14-2.81)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study evaluated the trends in anticoagulation use after total hip arthroplasty (THA), and the effectiveness and safety of rivaroxaban compared to warfarin. METHODS: This retrospective database analysis used healthcare claims from the Truven Health MarketScan database (2010-2015). Patients undergoing elective THA were followed for use of anticoagulants after surgery. Logistic regression models were used to compare differences in deep vein thrombosis (DVT), pulmonary embolism (PE), and adverse events, within 90 days after THA, among warfarin and rivaroxaban users. Inverse probability treatment weighting was used to account for selection bias. RESULTS: There were 12,876 users of warfarin and 10,892 users of rivaroxaban in commercially insured (CI) patients, and 7416 warfarin users and 4739 rivaroxaban users in Medicare supplement (MS) patients. Warfarin use decreased over time in both insurance cohorts, whereas rivaroxaban use increased from 2011 to 2015. Warfarin users were significantly more likely to experience both DVT (CI: odds ratio [OR] 2.63, 95% confidence interval 1.97-3.50; MS: OR 1.78, 95% confidence interval 1.38-2.29) and PE (CI: OR 2.60, 95% confidence interval 2.04-3.31; MS: OR 2.09, 95% confidence interval 1.66-2.65). There was no significant difference in rates of bleeding between the 2 agents, but warfarin users had higher odds of periprosthetic joint infection in both cohorts (CI: OR 1.57, 95% confidence interval 1.16-2.13; MS: OR 1.79, 95% confidence interval 1.14-2.81). CONCLUSION: There has been an increase in prophylaxis with rivaroxaban, and a decrease in warfarin use after elective THA over 4 years. Warfarin users were more likely to experience DVT and PE than rivaroxaban, and bleeding risks were similar.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Glassberg MB, Lachiewicz PF. Changing Patterns of Anticoagulation After Total Hip Arthroplasty in the United States: Frequency of Deep Vein Thrombosis, Pulmonary Embolism, and Complications With Rivaroxaban and Warfarin. J Arthroplasty. 2019. PMID: 31005440. doi:10.1016/j.arth.2019.03.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。